SF500
Ocampo 210 Bis – Predio CCT CONICET, Rosario, Santa Fe, 2000, Argentina
Overview
SF500 is a BioTech accelerator and VC fund. Founded in 2022. We turn science projects into Biotech startups. We search for outstanding science ideas and strong scientific and business people to build successful teams. We run a 12-week intensive program for 15 candidates with focus on science, team and product. A selection of the participants of our program receive a pre-seed investment of $250k. Our in-house dedicated portfolio management team keeps working with the founders, supporting all our portfolio startups from investment to the next stages. From legal and IP services to peer-to-peer support, lab facilities and connections to our network of international investors.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Advanced Materials
- Agriculture
- Biotechnology
- Food and Beverage
- Health Diagnostics
- Life Science
- Therapeutics
- Venture Capital
Investment portfolio
- Unibaio
Led · Seed · Apr 2023
SF500 is a venture investment fund that specializes in identifying, selecting, and financing high‑potential life sciences projects in Latin America. The firm is backed by Bioceres, an Argentine Nasdaq‑listed agricultural company with broad geographic presence and global strategic alliances. SF500 led a recent pre‑seed investment intended to help its portfolio company expand its team, continue innovating, and address current and future agricultural challenges. The fund's support is presented as a strategic endorsement that can help portfolio companies broaden their reach into the northern hemisphere and pursue expansion in the US market. The article highlights Bioceres' experience in agricultural innovation — including drought‑tolerant and herbicide‑tolerant crops — and frames that expertise as aligned with SF500's investment focus. SF500 closed a $500K deal on March 7 as part of the announced pre‑seed round.
- MultiplAI Health
Led · Seed · Mar 2023
MultiplAI Health develops a universal precision screening technology that combines RNA sequencing and artificial intelligence to produce a simple whole-blood liquid biopsy for cardiovascular and other complex diseases. The test is intended to deliver highly accurate risk assessments at a fraction of the cost of current screening options and to enable early detection and progressive tracking of CVD risk. The company says the universal test will help healthcare professionals identify cardiovascular risks before symptoms appear. MultiplAI launched in the UK in 2020 with support from Illumina Accelerator Cambridge and has since initiated clinical studies in the UK and Argentina. The firm maintains clinical and lab operations in Cambridge and Buenos Aires and is opening operations and partnerships in the United States. The $2.7M seed financing will be used for technical validation of its proprietary RNA-based, AI-driven product, team building, and US expansion.
Team
No current team members are available.